Overview

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Status:
Completed

Trial end date:
2016-04-22

Target enrollment:

Participant gender:

Summary

This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Desvenlafaxine Succinate